The role of RBE and LET in treatment efficacy of carbon ion radiotherapy for sacral chordoma
OC-0452
Abstract
The role of RBE and LET in treatment efficacy of carbon ion radiotherapy for sacral chordoma
Authors: silvia molinelli1, Giuseppe Magro2, Andrea Mairani3, Albina Allajbej4, Agnieszka Chalaszczyk5, Alfredo Mirandola2, Mario Ciocca2, Maria Rosaria Fiore5, Ester Orlandi5
1Fondazione CNAO, Medical physics, pavia, Italy; 2Fondazione CNAO, Medical Physics, pavia, Italy; 3Heidelberg Ion Beam Therapy Center , Radiation Oncology, Heidelberg, Germany; 4Istituto Nazionale dei Tumori, Radiation Oncology, Milano, Italy; 5Fondazione CNAO, Clinical Department, pavia, Italy
Show Affiliations
Hide Affiliations
Purpose or Objective
To understand the role
of relative biological effectiveness (RBE) modeling and dose-averaged linear
energy transfer (LETd) distribution in the treatment of sacral
chordoma (SC) patients with carbon ion radiotherapy (CIRT).
Material and Methods
We analyzed 50 SC
patients consecutively treated before August 2018, with a local effect model
(LEM)-based optimization, following a purely sequential boost schedule of 16
fractions (4.4 – 4.6 Gy(RBE) per fraction), with target shrinkage after 9
fractions. With a minimum follow-up of 12 months, 26 were classified as progressive disease; while 24 were
reported as stable disease or partial regression and populated the control
group for the analysis. To investigate patterns of failure, the relapse volume
was contoured on the corresponding follow-up diagnostic sequence and described
as in-field, field edge or out-of-field. Treatment plans were
recalculated with the modified microdosimetric kinetic RBE model (mMKM) and target prescription dose (DRBE|50%),
near-to-minimum- (DRBE|95%) and near-to-maximum- (DRBE|2%)
doses were compared, between the two cohorts, in both RBE systems. LETd
distribution was evaluated for in-field relapsed cases with respect to the
control group. A subset of cases was mMKM-optimized to test feasibility of a
new treatment protocol, aiming at the improvement of the therapeutic ratio. Finally,
the variation of LETd evaluators in relation to the RBE model used
for plan optimization was quantified.
Results
Half of the relapse
volumes were located in a well-covered high DLEM region, where DMKM
and LETd resulted sub-optimal (Figure 1). Recalculated target DMKM|50%
and DMKM|95% were respectively 10% and 18% lower than what we
aimed at. Dosimetric evaluators showed no significant difference, in neither of
the RBE models, between relapsed and control sets. On average, over these cases, median target LETd
was significantly lower than the control cohort mean value (27 vs 30 keV/mm) (Figure 1b). Most notably, the
volume receiving dose from high-LET particles (>50 keV/mm) lay substantially below recently reported data on the
Japanese experience. mMKM-optimization generated plans with LETd distributions
comparable to LEM-based, with no statistically significant difference in
neither of the considered criteria.
Figure
1 Optimized DLEM (a), recalculated DMKM
(b) and corresponding LETd (c) distributions of a high-dose relapsed
case. The colorwash scale normalization values are: a) DLEM = 70.4
Gy (RBE), b) DMKM = 67.2 Gy (RBE) and c) LETd = 50 keV/mm. Plotted contours
indicate the low dose - CTV (9 fractions - yellow), high dose - CTV (16
fractions - orange), GTV (red) and relapse (light blue) volumes.
Conclusion
Multi model RBE-evaluation
and LET-based optimization could play a key role in the enhancement of the
therapeutic ratio of CIRT for large radioresistant tumors such as sacral
chordomas.